Clinical Research Directory
Browse clinical research sites, groups, and studies.
ICG vs Blue Patent for TAD in cN1 Breast Carcinoma After Neoadjuvant Chemotherapy
Sponsor: Hospital Universitari de Bellvitge
Summary
To validate the use of ICG as a tracer during TAD in patients with cN1 breast carcinoma after neoadjuvant chemotherapy.
Official title: ICG vs Blue Patent as a Tracer in the Performance of TAD in Patients With cN1 Breast Carcinoma After Neoadjuvant Chemotherapy
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
43
Start Date
2021-01-01
Completion Date
2026-01-01
Last Updated
2025-04-22
Healthy Volunteers
No
Conditions
Interventions
Targeted axillary dissection (TAD) by ICG
Use of ICG during the targeted axillary dissection (TAD)
Targeted axillary dissection (TAD) by Blue patent
Use of Blue patent during the targeted axillary dissection (TAD)
Locations (1)
Hospital de Bellvitge
L'Hospitalet de Llobregat, Barcelona, Spain